Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Abigail K. Kois"'
1
Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48
Autor: Tomefa E Asempa, Abigail K Kois, Christian M Gill, David P Nicolau
Publikováno v: Journal of Antimicrobial Chemotherapy. 78:636-645
BackgroundTwo of the three recently approved β-lactam agent (BL)/β-lactamase inhibitor (BLI) combinations have higher CLSI susceptibility breakpoints (ceftazidime/avibactam 8 mg/L; meropenem/vaborbactam 4 mg/L) compared with the BL alone (ceftazidi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d270181319601aa6ae6e77924950954f
https://doi.org/10.1093/jac/dkac425
Zobrazit plný text záznamu
2
In vivo exposure–response relationship of meropenem against metallo-β-lactamase-harbouring Pseudomonas aeruginosa: an assessment using MICs from conventional and zinc-limited broth
Autor: Abigail K Kois, David P Nicolau, Tomefa E Asempa
Publikováno v: Journal of Antimicrobial Chemotherapy. 77:1938-1948
Objectives Previous investigations into metallo-β-lactamase (MBL)-harbouring Enterobacterales suggest that susceptibility testing in zinc-limited media may be more appropriate in predicting β-lactam in vivo activity. There are limited data with MBL
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c96416cc572726e417dab2a08b2f576e
https://doi.org/10.1093/jac/dkac141
Zobrazit plný text záznamu
4
Impact of a Pharmacist-Managed Procalcitonin Program on COVID-19 Respiratory Tract Infection Outcomes and Health Care Resource Utilization
Autor: Andrew J Fratoni, Abigail K Kois, Jessica L Colmerauer, Kristin E Linder, David P Nicolau, Joseph L Kuti
Publikováno v: Open Forum Infectious Diseases. 9
Patients hospitalized with coronavirus disease 2019 (COVID-19) often receive empiric antibiotic coverage. Procalcitonin (PCT) is a biomarker with Food and Drug Administration–approved guidance cutoffs for antibiotic use in lower respiratory tract i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::486890c3d9abe6b5d52d670e5bf73c76
https://doi.org/10.1093/ofid/ofac468
Zobrazit plný text záznamu
5
Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms
Autor: Joseph L. Kuti, David P. Nicolau, Abigail K Kois
Publikováno v: Current Opinion in Infectious Diseases. 33:482-494
Purpose of review Carbapenem-resistant organisms (CROs), including Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacterales, are a threat worldwide. This review will cover mechanisms of resistance within CROs and challenges with identific
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2b9ea9c72499e488816326b831eef91c
https://doi.org/10.1097/qco.0000000000000682
Zobrazit plný text záznamu
6
Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48
Autor: Tomefa E, Asempa, Abigail K, Kois, Christian M, Gill, David P, Nicolau
Publikováno v: The Journal of antimicrobial chemotherapy. 77(10)
Two out of the three recently approved β-lactam (BL)/β-lactamase inhibitors (BLIs) have higher CLSI susceptibility breakpoints (ceftazidime/avibactam 8 mg/L; meropenem/vaborbactam 4 mg/L) compared with the BL alone (ceftazidime 4 mg/L; meropenem 1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::309f5f132ca8f4a873eefa6db7b9e8d3
https://pubmed.ncbi.nlm.nih.gov/35325165
Zobrazit plný text záznamu
7
Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)
Autor: Abigail K. Kois, Jason A. Gluck, David P. Nicolau, Joseph L. Kuti
Publikováno v: International Journal of Antimicrobial Agents. 60:106603
This study determined the pharmacokinetics of cefepime in patients requiring extracorporeal membrane oxygenation (ECMO) support to guide dosage selection. Cefepime population pharmacokinetics where characterized in Pmetrics for R for six critically i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c575282ea304866f588d6045ff851638
https://doi.org/10.1016/j.ijantimicag.2022.106603
Zobrazit plný text záznamu
8
Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms
Autor: Abigail K, Kois, David P, Nicolau, Joseph L, Kuti
Publikováno v: Current opinion in infectious diseases. 33(6)
Carbapenem-resistant organisms (CROs), including Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacterales, are a threat worldwide. This review will cover mechanisms of resistance within CROs and challenges with identification and treatmen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4eb9ce40836413dff34fce587d360ba5
https://pubmed.ncbi.nlm.nih.gov/33009141
Zobrazit plný text záznamu
9
1241. In Vivo Efficacy of Meropenem Against Metallo-ß-Lactamase (MBL)-Harboring Pseudomonas aeruginosa and Correlation to In Vitro Susceptibility Upon Addition of EDTA
Autor: Abigail K Kois, Tomefa E Asempa, David P Nicolau
Publikováno v: Open Forum Infectious Diseases
Background Prior investigations evaluating the predictive value of zinc-depleted media for MBL-susceptibility testing have focused on Enterobacterales. Therein, bacterial killing observed with meropenem (MEM) in vivo was concordant with its pharmacod
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4785a08b280c222de5e7ed0d658b2a3d
http://europepmc.org/articles/PMC8643952
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje